Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
HOME > REGULATORY
REGULATORY
- MHLW to Promote Multinational Clinical Trials in East Asia to Reduce Drug Lag
February 23, 2012
- MHLW Plans to Set Up Medical Information Database at 6 Base Locations in FY2012
February 22, 2012
- MHLW to Improve Review System Based on Regulatory Science: PFSB Director General Yoshiyuki Kikura
February 22, 2012
- MHLW Warns Manufacturers to Take Steps to Ensure Proper Use of Anti-Influenza Drugs
February 22, 2012
- MHLW Issues Notification to Publicize FPMAJ’s Crude and Kampo Drug Standards
February 20, 2012
- MHLW Issues Improvement Order to Janssen Pharmaceutical for GMP Violation
February 20, 2012
- Domestic Pharmaceutical Production Down 0.6% in 2010; First Decline in Six Years
February 20, 2012
- 105 Nu-lotan Generics from 35 Companies Approved for June Listing, 60% Pricing to Apply
February 16, 2012
- Medical Innovation Council Executive Meeting to Set Next 5-Year Plan by May
February 16, 2012
- MHLW to Revise Notification on GMP Inspection Requirements to Prepare for Participation in PIC/S
February 16, 2012
- PAFSC’s 2nd Committee on New Drugs to Discuss Approval for Pfizer Japan’s ALK Inhibitor Xalkori
February 16, 2012
- Osaka Prefecture Asking Korosho to Provide Pharmaceutical Strategy Consultation Services in Kansai Region
February 16, 2012
- Over 30 Companies Target Nu-lotan Generic Listing in June, 60% Pricing Rule to Apply
February 15, 2012
- Prof. Matsumoto of OPMI Stresses Need to Enhance Competitiveness of Pharmaceutical Industry
February 14, 2012
- MHLW Postpones Ban of Dispensing Points to October
February 14, 2012
- PAFSC’s First Committee on Drugs to Review Astellas’ Hyperphosphatemia Treatment on February 24
February 14, 2012
- Healthcare Providers, Bill Payers in Face-Off Over Additional Premiums for Generic Name Prescriptions
February 13, 2012
- CSIMC’S Medical Fee Reform Plan for FY2012 to Promote Faster Patient Discharge, Functional Specialization
February 13, 2012
- FY2012 Medical Fee Revision to Include New Measures to Promote Generic Drug Use
February 13, 2012
- Guidance Fee for Psychiatric Patients to Be Reduced from 55 to 44 Points When Prescribing 3 or More Drugs
February 10, 2012
ページ
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…